Format

Send to

Choose Destination
Laryngoscope. 2019 Feb 12. doi: 10.1002/lary.27873. [Epub ahead of print]

Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation.

Author information

1
Multidisciplinary Larynx Cancer Working Group from the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
2
Department of Clinical Oncology, University of Alexandria, Alexandria, Egypt.
3
University of Texas McGovern Medical School, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, U.S.A.
4
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
5
Department of Otolaryngology, Houston Methodist Hospital, Houston, Texas, U.S.A.
6
Medical Physics Program, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, U.S.A.

Abstract

OBJECTIVES:

We aim to report oncologic outcomes after conventional radiotherapy (ConRT) using opposed lateral beams and intensity-modulated radiation therapy (IMRT) for tumor (T)1 nodal (N)0 T1 N0 glottic squamous cell carcinoma.

STUDY DESIGN:

Retrospective case-control study.

METHODS:

We retrospectively reviewed demographic, disease, and treatment characteristics for patients treated at our institution during 2000 to 2013.

RESULTS:

One hundred fifty-three patients (71%) were treated using ConRT and 62 (29%) using IMRT. The median follow-up for all patients was 68 months. There was no statistically significant difference in 5-year local control between patients with T1a versus T1b disease (94% vs. 89%, respectively, P = 0.5). Three-year locoregional control for patients treated with ConRT was 94% compared to 97% with IMRT (P = 0.4). Three-year overall survival (OS) for patients treated with ConRT was 92.5% compared with 100% with IMRT (P = 0.1). Twelve of 14 patients with local recurrence underwent salvage surgery with 5-year ultimate locoregional control of 98.5% and 97.1% in the ConRT and IMRT cohorts, respectively (P = 0.7). Multivariate analysis showed age < 60 years (P < 0.0001) and pretreatment Eastern Cooperative Oncology Group performance status <2 (P = 0.0022) to be independent correlates of improved OS. Postradiation cerebrovascular events were in four patients in the ConRT cohort (3%), whereas no patients in the IMRT cohort suffered any events.

CONCLUSION:

Because the oncologic outcomes for patients treated with IMRT were excellent and IMRT allows for carotid sparing, we have transitioned to IMRT as our standard for most patients with T1 glottic cancer.

LEVEL OF EVIDENCE:

3b. Laryngoscope, 2019.

KEYWORDS:

IMRT; T1 glottic squamous cell carcinoma; larynx cancer; oncologic outcomes; radiation therapy

PMID:
30756394
DOI:
10.1002/lary.27873

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center